Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) have received a consensus recommendation of “Buy” from the eight ratings firms that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $6.00.

A number of research analysts have weighed in on BDSI shares. Cantor Fitzgerald set a $5.00 target price on shares of BioDelivery Sciences International and gave the stock a “buy” rating in a research report on Friday, February 15th. Janney Montgomery Scott reissued a “buy” rating and set a $5.00 target price on shares of BioDelivery Sciences International in a research report on Thursday, January 31st. BidaskClub raised shares of BioDelivery Sciences International from a “sell” rating to a “hold” rating in a research report on Friday, January 11th. SunTrust Banks started coverage on shares of BioDelivery Sciences International in a research report on Tuesday, March 19th. They set a “buy” rating and a $7.00 target price for the company. Finally, HC Wainwright reissued a “buy” rating and set a $6.00 target price on shares of BioDelivery Sciences International in a research report on Friday, March 15th.

Shares of NASDAQ:BDSI opened at $4.65 on Thursday. The firm has a market capitalization of $329.93 million, a P/E ratio of -6.37 and a beta of 0.46. BioDelivery Sciences International has a 1 year low of $1.70 and a 1 year high of $5.37. The company has a debt-to-equity ratio of 1.74, a current ratio of 3.07 and a quick ratio of 2.82.

BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings results on Thursday, March 14th. The specialty pharmaceutical company reported ($0.10) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.10). The firm had revenue of $18.03 million during the quarter, compared to analyst estimates of $16.15 million. BioDelivery Sciences International had a negative net margin of 60.87% and a negative return on equity of 79.59%. As a group, equities analysts anticipate that BioDelivery Sciences International will post -0.24 EPS for the current year.

In other news, Director Healthcare Master Fun Broadfin sold 2,000,000 shares of the company’s stock in a transaction dated Thursday, April 11th. The shares were sold at an average price of $5.00, for a total transaction of $10,000,000.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Francis E. Odonnell, Jr. sold 23,000 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $5.07, for a total transaction of $116,610.00. Following the transaction, the director now directly owns 544,187 shares of the company’s stock, valued at approximately $2,759,028.09. The disclosure for this sale can be found here. Insiders have sold 2,048,050 shares of company stock valued at $10,241,990 in the last ninety days. 13.26% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Point72 Asset Management L.P. raised its position in shares of BioDelivery Sciences International by 150.0% during the third quarter. Point72 Asset Management L.P. now owns 1,500,000 shares of the specialty pharmaceutical company’s stock valued at $4,200,000 after buying an additional 900,000 shares during the last quarter. Barclays PLC raised its position in shares of BioDelivery Sciences International by 942.8% during the fourth quarter. Barclays PLC now owns 328,039 shares of the specialty pharmaceutical company’s stock valued at $1,214,000 after buying an additional 296,582 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of BioDelivery Sciences International by 121.7% during the third quarter. Wells Fargo & Company MN now owns 118,060 shares of the specialty pharmaceutical company’s stock valued at $331,000 after buying an additional 64,803 shares during the last quarter. Knott David M raised its position in shares of BioDelivery Sciences International by 33.8% during the fourth quarter. Knott David M now owns 500,300 shares of the specialty pharmaceutical company’s stock valued at $1,851,000 after buying an additional 126,300 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust acquired a new position in shares of BioDelivery Sciences International during the fourth quarter valued at about $615,000. 57.09% of the stock is owned by institutional investors and hedge funds.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Article: Real Estate Investment Trust (REIT) ETF

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.